

Gastroenterology Infusion

Call: (877) 883-1392 Fax: (256) 429-2221

Patient Information: Name:			DOB:	Gender: ○M ○F		
				State: Zip:		
Phone:	Alt.	Phone:	Email:	Ht:	Wt:	
Care Giver:		Allergies: O No Known C	O See Attached Charts O	ther:		
Last 4 of SSN:	: <u> </u>	Please include front and ba	ck copies of insurance card			
Prescriber I	nformation					
Name: NPI:			Phone:	Fax:		
Address:		City:	State: Zip:	Office Contact:		
	t of Medical Necessity (Please		nentation)			
	osis:					
○ Crohn's Disease ○ Ulcerative Colitis ○ Irritable Bowel Syndrome			Prior Failed Treatments	Drug Name & Length o	f Treatm	ent
ICD-10: Other: Serious or active infection present? O Yes O No			○ 5-ASA			
	-	○ Biologics				
•	ut or treatment started? OYes	○ Corticosteroids				
TB Test: OPositive ONegative Date:			 Immunosuppressants 			
Site of Infusion			○ Methotrexate			
	s Office OHospital Outpatient		○ Surgery			
○Infus	sion Center OPatient Home OC	Other:	○ Other			
nfusion Site II	nformation: (Required if Different	from Prescriber)				
		·		Citv:		
	Zip: NPI:		Phone:	Fax:		
	216 141 11		1 none.	1 ux.		
Medication	Dosage & Strength		Directions		Qty	Ref
○ Entyvio	○ 300mg/20ml Vial	Induction Dose:			1	0
		○Week 0: Infusion 300mg	g IV			
		○Week 2: Infusion 300mg	g IV		1	0
		○Week 6: Infusion 300mg	g IV		1	0
		Maintenance Dose:				
		○300mg IV 8 weeks after	the last IV dose, then every 8	3 weeks thereafter	1	
○ Remicade	○100mg/20ml Vial	Induction Dose: (adult an	nd pediatric patients)			
		OWeek 0: Infusion 5mg/k				
		OWeek 2: Infusion 5mg/k	kg IV			
		OWeek 6: Infusion 5mg/k	kg IV			
○ Refflicade		Maintenance Dose:				
		○5mg/kg IV 8 weeks after the last IV dose, then every 8 weeks thereafter				
		O (dose can be increased to 10mg/kg if patient				
		loses response to medica	tion later on)			
	○ 130mg/26ml Vial ○ 45mg/0.5ml Prefilled Syringe ○ 90mg/ml Prefilled Syringe	Induction Dose:			2	0
		OPatient Weight <55kg: 2	_		_	0
		OPatient Weight >55kg to			3	U
OStolara		OPatient Weight >85kg: 5	520mg IV		4	0
○Stelara	○90mg/ml Prefilled Syringe					
○Stelara	○ 90mg/ml Prefilled Syringe ○ 45mg/0.5ml Vial	Maintenance Dose:	aftautha isitial N/ daga thas	avam. O vessles the seasthan		
	○ 45mg/0.5ml Vial	Olnject 90mg SC 8 weeks	after the initial IV dose, then	every 8 weeks thereafter		
○Stelara			after the initial IV dose, then	every 8 weeks thereafter		
0	○ 45mg/0.5ml Vial	OInject 90mg SC 8 weeks		·	ices and p	atient
0	○ 45mg/0.5ml Vial ○ er Signature (I authorize pharma	OInject 90mg SC 8 weeks		rior authorizations, nursing serv		
OPrescribe	○ 45mg/0.5ml Vial ○ er Signature (I authorize pharma	OInject 90mg SC 8 weeks Oacy to act as my designee for initial	iating and coordinating insurance p	rior authorizations, nursing serv		
orescribe	○ 45mg/0.5ml Vial ○ er Signature (I authorize pharma	OInject 90mg SC 8 weeks Oacy to act as my designee for initial	iating and coordinating insurance p	rior authorizations, nursing serv		

<u>Confidentiality Notice</u>: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.